Dr. Stephen W. Stripling, M.D.
Pediatrics (Pediatrics Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Texas since 2000, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
SC license 20950 · TX license L0622 (first issued 2000; canc non-renewal)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 7 companies reported 21 payments worth $10,448 in total to this clinician.
| Lnhc, Inc | $10,224 |
|---|---|
| Collegium Pharmaceutical, Inc. | $63.23 |
| Merck Sharp & Dohme LLC | $54.42 |
| Tris Pharma Inc | $40.36 |
| Supernus Pharmaceuticals, Inc. | $35.61 |
| Sanofi-aventis U.S. LLC | $25.27 |
| Pfizer Inc. | $5.51 |
| Honoraria | $9,050 |
|---|---|
| Travel and Lodging | $830 |
| Food and Beverage | $451 |
| Gift | $117 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lnhc, Inc Aug 13, 2025 | Honoraria ZELSUVMI · DERMATOLOGY | $5,200 |
| Lnhc, Inc Nov 6, 2025 | Honoraria ZELSUVMI · DERMATOLOGY | $1,625 |
| Lnhc, Inc Nov 20, 2025 | Honoraria ZELSUVMI · DERMATOLOGY | $1,625 |
| Lnhc, Inc Aug 9, 2025 | Travel and Lodging ZELSUVMI · DERMATOLOGY · travel to IRVING, TX · in-kind | $623 |
| Lnhc, Inc Aug 13, 2025 | Honoraria ZELSUVMI · DERMATOLOGY | $600 |
| Lnhc, Inc Aug 9, 2025 | Travel and Lodging ZELSUVMI · DERMATOLOGY · travel to IRVING, TX · in-kind | $207 |
| Lnhc, Inc Aug 9, 2025 | Gift ZELSUVMI · DERMATOLOGY · in-kind | $117 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $125,814 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis
Arcutis Biotherapeutics, Inc. - A phase 2 randomized doubleblind trial to evaluate the safety tolerability and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy infants
Pfizer Inc. - A Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and Pharmacokinetic Study of Evening Dosed Methylphenidate Hydrochloride Extended?Release Capsul…
Collegium Pharmaceutical, Inc. - A phase 2 randomized partially doubleblind trial to evaluate the safety tolerability and immunogenicity of a multivalent pneumococcal conjugate vaccine administered in healthy toddlers 12 through 15 months of age
Pfizer Inc. - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
AbbVie Inc. · Completed · NCT05652205 - M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation
AbbVie Inc. - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.